Cutting-edge technology for breast cancer screening
Diagnostic-as-a-Service
that women need
Pain-free, low-cost, sensitive, radiation-free device to detect breast cancer in urine
The Problem
1 In 8 Women
will have breast cancer at least once
BC is the most treatable cancer
but 20 - 49 do not have reliable screening methods available
It still remains the #1 cancer killer for women
81% of them want to get tested for breast cancer
The Solution
We’re building a pain-free, radiation-free and accessible breast cancer test for them
Proof of concept data
"The Blue Box" (all women)
Mammography (women <50)
Sensitivity
Accuracy
Specificity
Sensitivity
Accuracy
Specificity
Sensitivity x1.5 higher than mammogram → less breast cancer patients left undiagnosed
High Specificity → less unnecessary 2nd assessments (biopsies, higher-radiation dose mammographies, additional radiological exams…)
Our Mission
Women aged 20-49 cannot get screened for breast cancer because existing solutions are unreliable. However, they want to, and are ready to pay for it. At “The Blue Box”, we have built a pain-free, low-cost, sensitive, radiation-free device to detect breast cancer in urine with a sensitivity of 88.33%.
Our Mission
Breast cancer is the most treatable cancer, yet it remains the #1 cancer killer for women, as 50% are detected too late. At The Blue Box, we’ve built a urine-based breast cancer test with a sensitivity of 88.42%, outperforming mammography by 15%-30%. We’ll run clinical trials in 2024 and launch in gynecology clinics by 2025.
“WomEC will revolutionize uterine cancer diagnosis in the world”
Javier F. Magrina,
Director Gynecologic Oncology
“From a clinical perspective, the project is expected to benefit the European community”
Frederic Amant,
Head of the gynecology oncology department, ex-chairman of the ENITEC consortium
Join The Blue Box Family!
Do you want to be the first to know when The Blue Box will hit the market?
Subscribe to our newsletter and never miss out on The Blue Box journey!
Scroll to Top
By clicking the “continue” button below and accessing the next page, the reader is declares she/he is clinician or scientific personnel and, therefore, can understand the content